Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
$7.90
-2.2%
$8.61
$56.35
$105.00
$228.98M0.9512,438 shs47,960 shs
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
$15.09
+5.7%
$13.06
$4.81
$27.50
$506.93MN/A324,882 shs154,165 shs
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
$11.62
-9.6%
$16.54
$2.80
$8.97
$418.99M0.6337,931 shs7.18 million shs
Tocagen Inc stock logo
TOCA
Tocagen
$11.00
-2.0%
$32.24
$0.42
$6.77
$263.11M0.011.47 million shs177,688 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
0.00%-4.01%+9.87%+8.97%-88.30%
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
0.00%+5.30%+9.75%+14.84%+1,508,999,900.00%
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
0.00%-13.93%-34.28%-19.47%-10.48%
Tocagen Inc stock logo
TOCA
Tocagen
0.00%-3.76%+10.22%+29.41%+39.24%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
2.1519 of 5 stars
3.50.00.00.02.11.70.6
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Tocagen Inc stock logo
TOCA
Tocagen
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
0.00
N/AN/AN/A
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
3.00
Buy$37.63149.34% Upside
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
0.00
N/AN/AN/A
Tocagen Inc stock logo
TOCA
Tocagen
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest TOCA, MBX, SBTX, and AVTE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/5/2025
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$38.00
7/16/2025
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$38.00
(Data available from 9/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
N/AN/AN/AN/A$3.96 per shareN/A
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/AN/AN/AN/AN/AN/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/AN/AN/AN/A$7.41 per shareN/A
Tocagen Inc stock logo
TOCA
Tocagen
$40K6,577.73N/AN/A$0.45 per share24.44
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
-$75.52M-$1.70N/AN/AN/AN/A-90.19%-77.47%11/10/2025 (Estimated)
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/A-$4.54N/AN/AN/AN/AN/AN/AN/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
-$89.48M-$2.42N/AN/AN/A-29.62%-28.20%N/A
Tocagen Inc stock logo
TOCA
Tocagen
-$63.52M-$2.69N/AN/AN/A-176,433.34%-327.74%-111.87%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
N/AN/AN/AN/AN/A
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/AN/AN/AN/AN/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/AN/AN/AN/AN/A
Tocagen Inc stock logo
TOCA
Tocagen
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
N/A
8.78
8.78
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/AN/AN/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/A
67.87
67.87
Tocagen Inc stock logo
TOCA
Tocagen
1.88
1.15
1.15

Institutional Ownership

CompanyInstitutional Ownership
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
N/A
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
74.89%
Tocagen Inc stock logo
TOCA
Tocagen
21.42%

Insider Ownership

CompanyInsider Ownership
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
24.90%
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
52.19%
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
34.40%
Tocagen Inc stock logo
TOCA
Tocagen
10.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
2028.99 million21.69 millionOptionable
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
3633.59 millionN/AN/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
8336.06 million23.65 millionNot Optionable
Tocagen Inc stock logo
TOCA
Tocagen
7723.92 millionN/ANot Optionable

Recent News About These Companies

Tocagen plummets on phase 3 data for glioma therapy
Celgene hopes device + drug can tackle aggressive brain tumours
Forte Biosciences Inc (FBRX)
RiskOn International And 3 Other Stocks Under $2 Insiders Are Buying

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aerovate Therapeutics stock logo

Aerovate Therapeutics NASDAQ:AVTE

$7.90 -0.18 (-2.23%)
As of 08/29/2025

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

MBX Biosciences stock logo

MBX Biosciences NYSE:MBX

$15.09 +0.82 (+5.75%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$15.04 -0.05 (-0.33%)
As of 08/29/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

Silverback Therapeutics stock logo

Silverback Therapeutics NASDAQ:SBTX

$11.62 -1.24 (-9.64%)
As of 08/29/2025

Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Tocagen stock logo

Tocagen NASDAQ:TOCA

Tocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells. The company's lead product candidate is Toca 511 & Toca FC that is under Phase III clinical trial for recurrent high-grade glioma. It is also developing Toca 511 & Toca FC in a Phase Ib clinical trial for intravenous treatment of advanced cancers. In addition, the company is developing other RRVs to deliver genes to cancer cells against validated immunotherapy targets. The company has a license agreement with ApolloBio to develop and commercialize Toca 511 & Toca FC; and a collaboration agreement with NRG Oncology to develop a clinical trial utilizing Toca 511 & Toca FC for the treatment of patients with newly diagnosed glioblastoma. Tocagen Inc. was founded in 2007 and is based in San Diego, California.